JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LOTTI, V. J.
Right arrow Articles by PORTER, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LOTTI, V. J.
Right arrow Articles by PORTER, C. C.
Journal of Pharmacology And Experimental Therapeutics, Vol. 172, Issue 2, 406-415, 1970
Copyright © 1970 by American Society for Pharmacology and Experimental Therapeutics

POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(—)-DOPA BY DECARBOXYLASE INHIBITORS

VICTOR J. LOTTI 1 and CURT C. PORTER 1

1 Merck Institute for Therapeutic Research, West Point, Pennsylvania

DL-agr-Methyl-agr-hydrazino-3,4-dihydrophenylpropionlc acid (HMD) and [N1-(DL-seryl)-N2-(2,3,4-trihydroxybenzyl) hydrazine] (Ro 4-4602), two known inhibitors of aromatic amino acid decarboxylase (dopa decarboxylase), were investigated for their effect upon some centrally mediated actions of l-dopa. HMD enhanced the ability of l-dopa to increase motor activity and irritability in mice and to increase motor activity in rats. In addition, HMD enhanced the reversal by L-dopa of reserpine-induced hypothermia, suppression of locomotion and ptosis. Enhancement of the pharmacologic actions of L-dopa by HMD was associated with enhanced brain dopamine levels. In contrast, the vomiting response to L-dopa in dogs and pigeons was attenuated by treatment with HMD. Low doses of Ro 4-4602 (1-125 mg/kg) potentiated l-dopa reversal of the locomotor suppressant and ptotic actions of reserpine; whereas, high doses (125-625 mg/kg) inhibited these actions of L-dopa. It is concluded that decarboxylase inhibitors can either inhibit or potentiate the central actions of i.-dopa depending upon whether they reach the brain sites where L-dopa acts.

Submitted on August 13, 1969
Accepted on November 26, 1969




This article has been cited by other articles:


Home page
 ScienceHome page
M. Wick
L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment
Science, February 17, 1978; 199(4330): 775 - 776.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics.